MK-2206 + anastrozole

MK-2206 + anastrozole is a combination therapy consisting of MK-2206, an allosteric pan-AKT inhibitor, and anastrozole, a nonsteroidal aromatase inhibitor. This combination has been investigated primarily for the treatment of estrogen receptor-positive (ER+), HER2-negative breast cancer. The rationale for combining these agents is based on the role of PI3K/AKT pathway activation in endocrine resistance in ER+ breast cancer. MK-2206 inhibits AKT signaling, potentially restoring sensitivity to endocrine therapy by promoting apoptosis in tumor cells. Anastrozole reduces estrogen production by inhibiting aromatase, thereby limiting estrogen-driven tumor growth[1][2][4]. Clinical trials have evaluated this combination in both metastatic and neoadjuvant settings; however, results indicate limited additional efficacy over anastrozole alone and notable toxicity concerns such as rash[1][2].